Our study identified a pharmacologically exploitable window for inhibiting the TRiC/CCT chaperonin complex in cancer, thereby revealing a therapeutic strategy that leverages the differential dependence of tumor cells on chaperonin function. The gene discussed is FLVCR2; the disease is neoplasm.